John F Palma

This inventor holds 11 USPTO granted patents and 10 published patent applications, plus 4 CIPO patents and 8 EPO patents. Top assignees: Metabolex, Inc., Roche Sequencing Solutions, Inc., Janssen Pharmaceutica Nv. Active years: 2006-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John F Palma. Retrieved from https://idiyas.com/inventor/john-f-palma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 11 (Patent Applications = 10)

% Patents Active = 45.5

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 10)

Average Co-Inventor Count = 4.2

ph-index = 3

Forward Citations = 63(Granted Patents)

Location History:

San Ramon, CA (US) (2006 - 2009)
Alamo, CA (US) (2022 - 2024)

Company Filing History:

Roche Sequencing Solutions, Inc.

patents

2 out of 2,101

Janssen Pharmaceutica Nv

Years Active: 2006-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12274711 - Method of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors (2025-04-14),

2. 12071661 - Method of predicting response to therapy by assessing tumor genetic heterogeneity (2024-08-27),

3. 11821041 - Non-invasive test to predict recurrence of colorectal cancer (2023-11-21),

4. 11559540 - Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors (2023-01-24),

5. 11519037 - Non-invasive test to predict response to therapy in colorectal cancer patients (2022-12-06),

6. 7491533 - Polynucleotides encoding an isolated β-islet cell two-pore domain potassium channel (2009-02-17),

7. 7405289 - Pancreatic islet transcription factor and uses thereof (2008-07-29),

8. 7374927 - Methods of analysis of degraded nucleic acid samples (2008-05-20),

9. 7294698 - Methods and reagents for diagnosis and treatment of diabetes (2007-11-13),

10. 7144985 - Methods and reagents for diagnosis and treatment of diabetes (2006-12-05),

11. 7053180 - Isolated islet beta-cell two-pore domain potassium channel (2006-05-30),

Title: John F. Palma: Innovator in Diabetes Research

Introduction

John F. Palma is a notable inventor based in San Ramon, California, recognized for his significant contributions to the field of diabetes research. With a total of six patents to his name, he has made substantial advancements that aim to improve the diagnosis and treatment of diabetes.

Latest Patents

Among his latest innovations are two pivotal patents:

1. **Polynucleotides Encoding an Isolated β-Islet Cell Two-Pore Domain Potassium Channel** – This invention offers polynucleotides that encode potassium channels, alongside methods for using these channels to treat and diagnose diabetes, as well as assess predisposition for the disease.

2. **Pancreatic Islet Transcription Factor and Uses Thereof** – This patent presents a transcription factor from pancreatic islets, which facilitates methods for treating and diagnosing diabetes.

Career Highlights

Throughout his career, John F. Palma has worked with some prominent companies, including Metabolex, Inc. and Affymetrix, Inc. His innovative approach and research have played a critical role in advancing treatments and understanding of diabetes.

Collaborations

John has collaborated with esteemed individuals in his field, including Jeffrey D. Johnson and John E. Blume. These partnerships highlight the collaborative nature of innovation in scientific research, especially in such a crucial area as diabetes.

Conclusion

In conclusion, John F. Palma stands out as a crucial inventor in the realm of diabetes research. His patents reflect a deep commitment to improving health outcomes for individuals affected by this condition. Through his work, he continues to pave the way for new methods of treatment and diagnosis in the ever-evolving field of medical science.

Profile summary based on public USPTO records.